Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 10;17(3):e0264149.
doi: 10.1371/journal.pone.0264149. eCollection 2022.

Characterization of a Neisseria gonorrhoeae Ciprofloxacin panel for an antimicrobial resistant Isolate Bank

Hsi Liu  1 , Kevin Tang  2 , Cau D Pham  1 , Matthew Schmerer  1 , Ellen N Kersh  1 , Brian H Raphael  1
Affiliations

Characterization of a Neisseria gonorrhoeae Ciprofloxacin panel for an antimicrobial resistant Isolate Bank

Hsi Liu et al. PLoS One. .

Abstract

Objectives: Neisseria gonorrhoeae (gonococcus) infection is one of the most commonly reported nationally notifiable conditions in the United States. Gonococcus has developed antimicrobial resistance to each previously used antibiotic for gonorrhea therapy. However, some isolates may be still susceptible to no longer recommended, yet still effective antibiotics. This in turn suggests that targeted therapy could slow resistance development to currently recommended empirical treatments. We curated a gonococcal Ciprofloxacin Antibiotic Resistance Isolate Bank panel (Cipro-panel) as a tool for validating or developing new tests to determine ciprofloxacin susceptibility.

Method: The Cipro-panel was selected using whole genome sequencing, bioinformatic tools, and antimicrobial susceptibility testing (AST) data. Isolates were further selected based on nucleotide variations in gyrA and parC genes.

Results: We selected 14 unique N. gonorrhoeae isolates from the 2006-2012 Gonococcal Isolate Surveillance Project (GISP) collection. They represented a wide range of antimicrobial susceptibility to ciprofloxacin and commonly observed nucleotide variations of gyrA and parC genes. This Cipro-panel consists of 5 isolates with resistant phenotypes (MIC > = 1 μg/mL), 8 isolates with susceptible phenotypes (MIC < = 0.06 μg/mL), and 1 isolate falling in the Clinical and Laboratory Standards Institute defined intermediate range. Among the gyrA variations we observed a total of 18 SNPs. Four positions had nonsynonymous changes (nucleotide positions 272, 284, 1093, and 1783). The first two positions (272 and 284) have been linked previously with resistance to ciprofloxacin (i.e. amino acid positions 91 and 95). For the parC gene, we observed a total of 21 possible SNPs. Eight of those SNPs resulted in non-synonymous amino acid changes. One location (amino acid 87) has been previously reported to be associated with ciprofloxacin resistance.

Conclusions: This Cipro-Panel is useful for researchers interested in developing clinical tests related to ciprofloxacin. It could also provide additional choices for validation, quality assurance purposes and improve antibiotic usage.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, et al.. 2019. Chlamydia, gonorrhea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ 97: 548–562. https://www.who.int/bulletin/volumes/97/8/18-228486.pdf (Accessed May 6, 2020). doi: 10.2471/BLT.18.228486 - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention (CDC). 2021. Gonorrhea. Sexually Transmitted Disease Surveillance 2019. https://www.cdc.gov/std/statistics/2019/default.htm (Accessed August 6, 2020).
    1. Centers for Disease Control and Prevention. 2004. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men—United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR 2004. 53: 335–338. https://www.ncbi.nlm.nih.gov/pubmed/15123985 (Accessed May 8, 2020). - PubMed
    1. Centers for Disease Control and Prevention. 2007. Update to CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infection. MMWR. 56(14) 332–336. Accessed May 6, 2020, https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5614a3.htm. - PubMed
    1. Centers for Disease Control and Prevention. 2020. Update to CDC’s treatment guidelines for gonococcal infection, 2020. MMWR. 50: 1911–1916. https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm (Accessed May 6, 2020). doi: 10.15585/mmwr.mm6950a6 - DOI - PMC - PubMed

MeSH terms